Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury, Hitomi Hosoya, Rebecca M Gonzalez, Christina Copponex, Krista H Kottra, Vanna Hovanky, Bita Sahaf, Sunita Patil, Aleksandr Lazaryan, Michael D Jain, Aliyah Baluch, Olga V Klinkova, Nelli Bejanyan, Rawan G Faramand, Hany Elmariah, Farhad Khimani, Marco L Davila, Asmita Mishra, Brandon J Blue, Ariel F Grajales-Cruz, Omar A Castaneda Puglianini, Hien D Liu, Taiga Nishihori, Ciara L Freeman, Jason B Brayer, Kenneth H Shain, Rachid C Baz, Frederick L Locke, Melissa Alsina, Surbhi Sidana, Doris K Hansen
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize cytopenias and infections within 100 days after ide-cel in the standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data were censored at day 100. Grade ≥ 3 cytopenia was present among 65% of patients at day 30 and 40% of patients at day 90...
December 27, 2022: Blood Advances